CardioFocus has announced that its HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions (9–12 May, Boston, USA). The presentations will feature clinical experiences and outcomes using the company’s technology.
“We are pleased that over two years of comprehensive clinical experiences with our technology will be featured at this prominent industry conference. Many of the leading international experts in heart rhythm management will be participating in these sessions and presenting their own findings with the HeartLight EAS, and we anticipate engaging discussion on the applicability of the system in clinical practice,” said Stephen Sagon, president and CEO, CardioFocus.
During the scientific sessions, the presentation “Worldwide experience using the endoscopic ablation system for ablation of atrial fibrillation” will give an overview of the feasibility and safety of atrial fibrillation ablation using the HeartLight EAS, with findings representing the first patients treated with the technology by 32 different operators across 19 medical centres. The presentation will be made by Boris Schmidt, Cardioangiologisches Centrum Bethanien, Frankfurt, Germany.
About the HeartLight EAS
The HeartLight EAS incorporates an endoscope for direct visualisation of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the pulmonary vein ostium irrespective of the individual patient anatomy. It also utilises laser energy for more efficient, durable and precise ablation treatment.
The system is available in Europe for the treatment of atrial fibrillation, and is currently the focus of a pivotal trial in the USA.
